Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 23.25 (-0.24), UTHR: 111.16 (+1.58), AZN: 30.11 (unch)
Arena (ARNA) to Cut 73% Workforce, Shifts Focus to Pipeline
Arpita Dutt - Zacks Investment Research - Fri Jul 01, 8:37AM CDT
Arena (ARNA) is looking to reduce costs through a 73% reduction in its workforce.
ANIP: 56.51 (-1.61), VVUS: 1.18 (+0.02), ARNA: 1.70 (+0.06)
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 7.15 (+0.32)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 122.85 (+0.34), GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), AMGN: 161.10 (+4.51), ABBV: 64.16 (+0.73), RDY: 53.69 (+0.79), AVXS: 37.70 (+0.98), NVS: 82.13 (+0.33)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 29.35 (+0.23), CLSN: 1.30 (unch), JAZZ: 139.88 (+1.40)
Corcept's (CORT) Q4 Earnings Impress, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 10:00AM CST
Corcept Therapeutics Incorporated (CORT) reported earnings of 1 cent per share in the fourth quarter of 2015, while Zacks Consensus Estimates was a loss of 2 cents
PETX: 7.00 (+0.31), TRIL: 8.80 (+0.08), CORT: 6.01 (+0.14)
Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 9.11 (unch), BXLT: 46.02 (-0.18)
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 9.14 (+0.26), BXLT: 46.02 (-0.18), ARNA: 1.70 (+0.06)
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 9.14 (+0.26), BXLT: 46.02 (-0.18), ARNA: 1.70 (+0.06)
Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 139.88 (+1.40), TEVA: 50.89 (+0.37), CNCE: 11.80 (+0.01)
Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 10:35AM CDT
Corcept Therapeutics (CORT) posted loss of a penny per share in the second quarter of 2015, narrower than both the Zacks Consensus Estimate of a loss of 5 cents.
VRX: 23.25 (-0.24), ANAC: 99.06 (-0.14), CORT: 6.01 (+0.14)
Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 8:10AM CDT
Although Arena Pharmaceuticals' (ARNA) second quarter loss was narrower-than-expected, revenues missed expectations.
GILD: 86.55 (+1.08), ARNA: 1.70 (+0.06)
Will Epizyme (EPZM) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 12:40PM CDT
Epizyme (EPZM) has an Earnings ESP of 3.08% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
INO: 9.11 (+0.03), EPZM: 10.31 (+0.39), GSK: 43.38 (+0.04)
Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 12:00PM CDT
Investor focus will remain on the performance of Arena's (ARNA) obesity treatment - Belviq.
BDSI: 2.58 (+0.07), VVUS: 1.18 (+0.02), ARNA: 1.70 (+0.06)